REG - Oxford BioDynamics - Results of GM
03/04/2024 13:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240403:nRSC1898Ja&default-theme=true
RNS Number : 1898J Oxford BioDynamics PLC 03 April 2024
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW
ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER
JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE
MEANINGS GIVEN TO THEM IN THE DEFINITIONS SECTION OF THE CIRCULAR TO
SHAREHOLDERS OF THE COMPANY DATED 14 MARCH 2024.
Oxford BioDynamics PLC
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Result of General Meeting
Director/PDMR Dealings
3 April 2024 - Oxford BioDynamics PLC (AIM: OBD), a biotechnology company
developing precision medicine tests based on the EpiSwitch® 3D genomics
platform announces that both resolutions proposed at the General Meeting of
the Company, held earlier today, were duly passed.
Further to the passing of the resolutions at the General Meeting, application
has been made for 18,234,454 new Ordinary Shares (comprising the VCT/EIS
Placing Shares to be issued pursuant to the Placing) to be admitted to trading
on AIM ("VCT/EIS Admission"). Application has also been made for 91,317,781
new Ordinary Shares (comprising the General Placing Shares, the Subscription
Shares and the PrimaryBid Shares to be issued pursuant to the Placing, the
Subscriptions and the PrimaryBid Offer) to be admitted to trading on AIM
("General Admission").
It is expected that VCT/EIS Admission will take place, and trading in the
VCT/EIS Placing Shares will commence, at 8.00 a.m. on 5 April 2024 and that
General Admission will take place, and trading in the General Placing Shares,
the Subscription Shares and the PrimaryBid Shares will commence at 8.00 a.m.
on 8 April 2024.
Following VCT/EIS Admission, the Company's issued ordinary share capital and
total voting rights will consist of 220,537,869 Ordinary Shares. Following
General Admission, the Company's issued ordinary share capital and total
voting rights will consist of 311,855,650 Ordinary Shares. These figures
should be used by shareholders as the denominator for the calculation by which
they determine if they are required to notify their interest in, or a change
to their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
The total New Ordinary Shares subscribed for pursuant to the Placing, the
Subscriptions and the PrimaryBid Offer by the Directors and PDMRs who are
participating in the Fundraising, are set out below:
Director/PDMR Existing beneficial shareholding Fundraising Shares Beneficial shareholding following the Fundraising Shareholding as a percentage of the Enlarged Share Capital
Dr Alexandre Akoulitchev 6,603,082 333,333 6,936,415 2.22%
Dr Jon Burrows 700,000 388,888 1,088,888 0.35%
Stephan Diggle(1) 27,431,756 2,222,222 29,653,978 9.51%
Thomas Guiel 365,000 258,888 623,888 0.20%
Dr Ewan Hunter 136,363 55,555 191,918 0.06%
Paul Stockdale 331,818 166,666 498,484 0.16%
Matthew Wakefield(2) 1,022,727 277,777 1,300,504 0.42%
(1) Stephen Diggle's beneficial shareholding is held through the Vulpes Life
Sciences Fund and Vulpes Testudo Fund, which are controlled by him.
(2) Matthew Wakefield's beneficial shareholding includes shares owned by his
wife, Mrs Carla Wakefield.
Following on from the Company's announcement on 13 March 2024, Baden Hill, a
related party of the Company, will receive commission of £167,135 in relation
to their role as joint broker on the Fundraising.
Director/PDMR Dealings
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Matthew Wakefield
2 Reason for the notification
a) Position/status Chairman
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.09 277,777
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 3 April 2024
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
3 April 2024
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Jon Burrows
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.09 388,888
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 3 April 2024
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
3 April 2024
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Alexandre Akoulitchev
2 Reason for the notification
a) Position/status Chief Scientific Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.09 333,333
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 3 April 2024
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
3 April 2024
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Paul Stockdale
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.09 166,666
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 3 April 2024
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
3 April 2024
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Vulpes Investment Management (a PCA of Stephen Diggle) through Vulpes Testudo
Fund
2 Reason for the notification
a) Position/status Person closely associated with Non-Executive Director
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.09 2,222,222
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 3 April 2023
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
3 April 2023
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Thomas Guiel
2 Reason for the notification
a) Position/status Chief Operating Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.09 258,888
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 3 April 2024
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
3 April 2024
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Ewan Hunter
2 Reason for the notification
a) Position/status Chief Data Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.09 55,555
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 3 April 2024
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
3 April 2024
f)
Place of the transaction
Off market
For further details please contact:
Oxford BioDynamics PLC +44 (0)1865 518910
Jon Burrows, CEO
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Joint Broker +44 (0)20 7408 4090
Advisory: Stephane Auton / Iain Sexton
Broking: Fiona Conroy
Baden Hill (a trading name for Northland Capital Partners Limited) - Joint +44 (0)20 3951 8907
Broker
Alex Schlich
WG Partners - Joint Broker +44 (0)20 3705 9330
David Wilson / Claes Spång / Sateesh Nadarajah / Erland Sternby
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Jack Kincade OxfordBioDynamics@instinctif.com
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.
Its flagship products are the EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
(Checkpoint Inhibitor Response Test) and EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86NjBhZjhlZjA4OTJlYWM2OTZhMzcyN2MyMjJjZmUyMjQ6Njo2ZGEzOmZhODNhNDE4MWMxNTY5MDMzNGUwYTA2MGE3OTU3Nzk0NDMzZTY1MjVhMjcwZjM3NDdmYjI2MmExM2JiMDQxMmE6cDpU)
(EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune
response profile for immuno-oncology (IO) checkpoint inhibitor treatments,
launched in February 2022. PSE is a blood test that boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer, which was launched in the US and UK in September 2023.
In March 2021, the Company launched its first commercial prognostic
test, EpiSwitch® CST
(https://url.avanan.click/v2/___https:/covidseveritytest.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpmZWY1OmMzOGIyYTk2Yjk1OTgyMDNlMGFkNmQwZGU3ZmNmYzQwMzZmMGIwZDQ5NzA0OTAzNDc0NzY2ZDQyZGZiYjk5YWU6cDpU)
(Covid Severity Test) and the first commercially available microarray kit
for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit
(https://url.avanan.click/v2/___https:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpiMWU2OjMzMTc0NWQ5ZWZhODg0MmY1N2EzZjY2YWRkZDI5YjBkOTRhM2M0ZTZkOGJkNWM2Y2I5MDE4MmQ4M2Y4ZjViMDY6cDpU)
, which is available for purchase by the life science research community.
The Company's product portfolio is based on a proprietary 3D genomic biomarker
platform, EpiSwitch®, which can build molecular diagnostic classifiers for
the prediction of response to therapy, patient prognosis, disease diagnosis
and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 15,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg and a clinical
laboratory in Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.
For more information, please visit the Company's
website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCQKNBPDBKDPQKRecent news on Oxford Biodynamics
See all newsREG - Oxford BioDynamics - Holding(s) in Company
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
Announcement